Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsCAPSULEGeneric

NINTEDANIB

NINTEDANIB

Standard Dose
25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview NINTEDANIB is listed in Drugs@FDA under application 219371 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NINTEDANIB Form and strength CAPSULE - 25MG Sponsor TEVA PHARMACEUTICALS DEVELOPMENT INC Submission history Latest submission status date: 2026-03-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview NINTEDANIB is listed in Drugs@FDA under application 219371 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NINTEDANIB Form and strength CAPSULE - 25MG Sponsor TEVA PHARMACEUTICALS DEVELOPMENT INC Submission history Latest submission status date: 2026-03-26 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.